Practice Tool: Talking About Seizures and Rescue Therapies

What is a rescue therapy?

- Antiseizure medication used 'prn' (as needed) to stop seizure clusters or seizures that last longer than usual
- Stops seizures or clusters from becoming seizure emergencies
- Intended for out-of-hospital use by nonmedical people
- Does not take the place of daily antiseizure medications or emergency care
- If prescribed, a rescue therapy must be part of the person's seizure action plan

FDA-Approved Rescue Therapies for Administration by Nonmedical People

Every person with epilepsy should have

a seizure action plan.

Every person with epilepsy should be

assessed for a rescue therapy.

Rescue Therapy/ Age Indication	Dosage and Administration	Bioavailability	Peak (T _{max})	Half-life (T ½)
Diazepam rectal gel (Diastat) ≥ 2 yrs	 Unit doses: 2.5, 5, 7.5, 10, 12.5, 15, 17.5, or 20 mg Dosage based on age and weight A 2nd dose may be given 4–12 hrs after 1st dose, as needed 	90%	1.5 hrs	46 hrs (parent compound) 71 hrs (active metabolite)
Diazepam nasal spray (Valtoco) ≥ 6 yrs	 Dosage strength: 5 and 10 mg (single spray), 15 or 20 mg (2 nasal spray devices) Dosage based on age and weight A 2nd dose may be given ≥ 4 hrs after 1st dose, as needed 	97%	1.5 hrs	49 hrs
Midazolam nasal spray (Nayzilam) ≥ 12 yrs	 Provided in a unit dose: 5 mg A 2nd 5-mg dose may be given 10 min after 1st dose (in opposite nostril), as needed 	44%	17 min	2–6 hrs (parent compound) 2–7 hrs (active metabolite)

How do nasally administered rescue medications compare with rectal diazepam gel?

• Nasally administered rescue medications are easier to use, cause less somnolence, and have a faster onset of action (nasal spray: 1 to 5 min; rectal gel, 2 to 15 min)

When should a rescue therapy be prescribed?

Plans for rescue therapy use should be individualized for each person with epilepsy.

What to assess when evaluating the need for a rescue therapy

- Seizure clusters or seizures lasting longer than usual
- Convulsive seizures lasting > 5 minutes
- History of status epilepticus or other seizure emergencies
- Recent prolonged seizures or clusters of febrile seizures
- History of first seizure lasting > 5 min, multiple seizures, or status epilepticus prior to starting treatment
- Specific situations or triggers that may be associated with change in seizures
- Seen in emergency room or hospitalized for seizures
- Needed rescue therapy in past
- Safety concerns during seizures
- Seizures with prolonged aura/warning

Ways to start the conversation

- "What words do you use to describe your seizures?"
- "How often do you have a seizure? How long do they usually last?"
- "Have you had periods or groups of seizures that are different from usual? What do you call these?"
- "Is there anything special you do when these happen?"
- "Have you ever heard about treatments for seizure clusters?"

When to talk about rescue therapies

- At the time of diagnosis
- Change in seizure pattern (more frequent, change in type, breakthrough)
- Triggers identified that are associated with increased or breakthrough seizures
- New treatment-related concerns (seen in emergency room or hospitalized for seizures, change in treatment)
- Change in health status (changes in comorbidities or general health, pregnancy, injury)
- Change in developmental status
- Change in care setting or providers (eg, from pediatric to adult, hospital to school, hospital to home)
- Life changes or stressors

Common questions that people may have about rescue medication

- "What is it and why do I need it?"
- "Who can give it? Can I give it to myself?"
- "When do I use it and how?"
- "They [school, daycare, work, community provider] say they can't give it. What do I do?"
- "What do I do if I live alone? How can I get help?"

Where can I find a seizure action plan?

- Epilepsy Alliance America ASAP (English, Spanish) <u>https://www.epilepsyallianceamerica.org/programs-services/seizure-action-plan/</u>
- Epilepsy Foundation SAP (English, Spanish, Chinese, Korean, Tagalog, Vietnamese) <u>https://www.epilepsy.com/preparedness-safety/action-plans</u>
- Seizure Action Plan Coalition (English, Spanish) https://seizureactionplans.org/sap-examples/
- Child Neurology Foundation (English, Spanish)
 https://www.childneurologyfoundation.org/epilepsy-education-hub/

How can I make seizure action plans a part of everyday practice?

- Put a seizure action plan form in new-patient information packages start talking about it at first visit
- Ask patient/care partner to start filling in the form; bring to next visit or discuss on follow-up call
- Keep forms in the exam room, online, or with office staff
- Share the seizure action plan with everyone on patient's health care team
- Ask patient/care partner to give copies to other providers and people who help them during seizures
- Discuss and/or demonstrate how to talk about seizures and the plan with friends and family
- Include the seizure action plan in visit summaries and the patient's electronic health record



Where can patients learn more about rescue therapies and seizure action plans?

• Time to Talk About Seizures and Rescue Therapies www.conversationsaboutepilepsy.org

This educational handout is from *Starting Now: Conversations About Seizure Rescue Therapies*, a CE activity supported by an educational grant from Neurelis, Inc. and developed by CMEology and Medical Education Resources. Copyright © 2023 by CMEology. References: Buchhalter J, et al.

Epilepsy Behav. 2021;117:107836. Shafer PO, et al. *Epilepsy Behav.* 2021;125:108444. Drugs@FDA: FDA-approved drugs. Prescribing information for each medication listed. Accessed January 21, 2023. <u>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm</u>. Vossler DG, et al. A summary of antiseizure medications available in the United States: 2020 update. American Epilepsy Society. Revised September 10, 2020. Accessed January 21, 2023. <u>https://www.aesnet.org/docs/defaultsource/pdfs-clinical/2020-september-aes_summary_of_asms.pdf?sfvrsn=c1a0ed0b</u>. Gidal B, et al. *Epilepsy Behav.* 2020;112:107391. Hogan RE, et al. *Epilepsia*. 2020;61(3):455-464. US FDA. Clinical superiority findings. Reviewed June 24, 2021. Accessed Dec 20, 2022. <u>https://www.fda.gov/industry/designating-orphan-</u> product-drugs-and-biological-products/clinical-superiority-findings.